Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Inhibitory Control Clear all
Recruiting Phase 2 Interventional

A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)

NCT07409103
View directory record Official record
Conditions
Active Rheumatoid Arthritis
Interventions
ELV001 25 mg, ELV001 75 mg, ELV001 125 mg, Placebo
Drug
Lead sponsor
Elevara Medicines Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
22
States / cities
Gilbert, Arizona • Glendale, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 3, 2026, 5:45 AM EDT
Completed Not applicable Interventional

Response Inhibition Training for Individuals With Trichotillomania

NCT01638975
View directory record Official record
Conditions
Trichotillomania
Interventions
Response Inhibition Training Program
Behavioral
Lead sponsor
University of Wisconsin, Milwaukee
Other
Eligibility
9 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 19, 2014 · Synced Sep 3, 2026, 5:45 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion

NCT06123026
View directory record Official record
Conditions
Lactation Suppressed, Second Trimester Abortion
Interventions
Cabergoline, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Sep 3, 2026, 5:45 AM EDT
Not yet recruiting Phase 2 Interventional

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

NCT07783802
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Interventions
Clazakizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
31
States / cities
Huntsville, Alabama • Tucson, Arizona • Glendora, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 3, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia

NCT02871778
View directory record Official record
Conditions
Primary Ciliary Dyskinesia
Interventions
VX-371, Hypertonic Saline, Placebo (0.17% saline), VX-371 + HS, Ivacaftor
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
12 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Sep 3, 2026, 5:45 AM EDT
Completed Not applicable Interventional

Online Response Inhibition Training for Trichotillomania

NCT01984333
View directory record Official record
Conditions
Trichotillomania
Interventions
Online cognitive training
Behavioral
Lead sponsor
University of Wisconsin, Milwaukee
Other
Eligibility
8 Years to 17 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Sep 3, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx

NCT03220854
View directory record Official record
Conditions
Solid Tumor
Interventions
Stereotactic radiotherapy, Biological: humanized anti-PD-1 monoclonal antibody, Biological: humanized anti-PD-L1 monoclonal antibody
Radiation · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 9, 2022 · Synced Sep 3, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

NCT01763866
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe, Atorvastatin, Rosuvastatin, Simvastatin
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
65
States / cities
Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 3, 2026, 5:45 AM EDT
Completed Phase 3 Interventional

Using Drug Levels in the Blood to Guide Therapy in HIV Infected Patients Taking a Protease Inhibitor

NCT00041769
View directory record Official record
Conditions
HIV Infections
Interventions
Therapeutic Drug Monitoring (TDM)
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
46
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2010 · Synced Sep 3, 2026, 5:45 AM EDT
Recruiting Not applicable Interventional

Brief Inhibitory Training for Eating - Intervention

NCT07592728
View directory record Official record
Conditions
Overweight and/or Obesity
Interventions
Daily inhibitory control training
Behavioral
Lead sponsor
George Mason University
Other
Eligibility
14 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 3, 2026, 5:45 AM EDT
Terminated Phase 4 Interventional

Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS

NCT00486343
View directory record Official record
Conditions
Asthma
Interventions
Zileuton CR, Placebo
Drug
Lead sponsor
Critical Therapeutics
Industry
Eligibility
12 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 2, 2008 · Synced Sep 3, 2026, 5:45 AM EDT
Recruiting Not applicable Interventional

Drumming Lessons' Influence on Children With Down Syndrome

NCT07156318
View directory record Official record
Conditions
Down Syndrome
Interventions
2 months of drumming lessons given by a professional drummer with extensive experience working with children with Down syndrome, Lessons after measurement
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
7 Years to 15 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 3, 2026, 5:45 AM EDT
Recruiting Phase 2 Interventional

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

NCT07685808
View directory record Official record
Conditions
Overweight or Obesity
Interventions
Olatorepatide, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Walnut Creek, California • Maitland, Florida • The Villages, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 3, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ

NCT00567164
View directory record Official record
Conditions
Contraception, Ovulation Inhibition, Contraceptives, Oral
Interventions
EE20/DRSP (BAY86-5300), EE20/DRSP (YAZ, BAY86-5300)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,887 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
85
States / cities
Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Sep 3, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

NCT00390455
View directory record Official record
Conditions
Estrogen Receptor Positive, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Fulvestrant, Laboratory Biomarker Analysis, Lapatinib Ditosylate, Placebo Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
368
States / cities
Little Rock, Arkansas • Arroyo Grande, California • Burbank, California + 259 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Sep 3, 2026, 5:45 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Topical 0.4% Ketorolac and Vitreoretinal Surgery

NCT00576329
View directory record Official record
Conditions
Surgery
Interventions
Ketorolac
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 3, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2

NCT01763918
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Scottsdale, Arizona • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 16, 2019 · Synced Sep 3, 2026, 5:45 AM EDT
Terminated Phase 3 Interventional Results available

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs

NCT01209702
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
tocilizumab, Placebo
Biological · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
15
States / cities
Huntington Beach, California • Aventura, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 3, 2026, 5:45 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.

NCT05059236
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer
Interventions
Darolutamide (BAY1841788, Nubeqa), ADT
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
31
States / cities
Homewood, Alabama • Tucson, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 3, 2026, 5:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Exposure to a Single-electrode Electroencephalography-guided Binaural Beat Audio Track on Sustained Attention and Subjective Well-being Among Healthy Adults

NCT07165899
View directory record Official record
Conditions
Psychomotor Speed, Sustained Attention, Inhibitory Control, Memory Encoding, Well-being
Interventions
EEG-Guided Binaural Beat Audio, Sham Control
Behavioral
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 3, 2026, 5:45 AM EDT
Completed No phase listed Observational

Behavior in Children With Attention Deficit Hyperactivity Disorder and in Healthy Volunteers

NCT00026546
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
8 Years to 17 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 3, 2026, 5:45 AM EDT
Terminated Phase 2 Interventional

A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung Bypass

NCT00271167
View directory record Official record
Conditions
Heart Diseases, Postoperative Complications
Interventions
INO-1001
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 90 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
5
States / cities
Boston, Massachusetts • Oklahoma City, Oklahoma • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 3, 2026, 5:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life

NCT02945371
View directory record Official record
Conditions
Smoking, Alcohol Drinking, Prescription Drug Abuse, Substance-Related Disorders, Oral Intake Reduced
Interventions
Person-centered inhibitory control training, Active behavioral response training
Behavioral
Lead sponsor
University of Oregon
Other
Eligibility
35 Years to 55 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Sep 3, 2026, 5:45 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition

NCT00780325
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CG100649 (2 mg), Celecoxib, Placebo capsules, Naproxen, Acetazolamide, CG100649 (8 mg)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Sep 3, 2026, 5:45 AM EDT